With BlackBerry Limited (NYSE:BB) price’s latest movement, it is now -37.44% away from its 1-year high and 27.40% higher than its 1-year low price. In the past seven days, the stock price volatility for BlackBerry Limited was 2.21%, whereas its volatility in the past 30 days has been 2.07%. This public company’s stock also has a beta score of 2.05. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.
BlackBerry Limited (NYSE:BB) most recently published its quarterly earnings results. The firm posted $0.05 earnings per share (EPS) for the three-month period, surpassing analysts’ consensus estimate of $0.02 by $0.03. The publicly-traded organization reported revenue of $228.00 million for the quarter, compared to the average analyst forecast calling for $214.45 million, which was surpassing the analyst consensus estimate.
Shares of BlackBerry Limited (BB) plunged -1.76%, amounting to a loss of -$0.15 per share, to finish the regular trading session at $8.37 on Thursday 02/21/2019. After beginning the session at $8.5, shares of BlackBerry Limited reached as high as $8.535 during the day, while hitting a 1-day low of $8.36. Trade volume reached 3,468,293 shares against this stock’s average daily volume of 3.64M shares, with a total float of 536.47M. As a consequence of the price decrease, BlackBerry Limited now has a current market value of 4.49B.
Zosano Pharma Corporation (NASDAQ:ZSAN) added 171.49% to its trading price by the close of the most recent session, jumping from its previous closing price of $2.21 to $6.00. This stock increased in value by 150.00% during the last 7-day period, and experienced a gain of 173.97% over the past 30-day period. In the past three months, this stock’s price grew by 55.84% , and added 51.13% to its price during the last six months of trading. ZSAN demonstrated a yearly price gain of 34.53% , while its year-to-date (YTD) price performance has been up 183.02% . This stock’s price changed by +224.32% compared to its 90-day low, and moved down -9.77% comparing to its 90-day high price.
Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the ZSAN stock as “Hold”. In the short-term, Zosano Pharma Corporation (ZSAN) has a 20-day average volume of 4,029,235 shares and short-term indicators sets the ZSAN stock as “ 60% Buy ” on average basis. In the medium-term, ZSAN stock has a 50-Day average volume of 1,695,806 shares and medium-term indicators gave the average rating of “ 50% Buy ”, while in the long-term period the FB stock has a 100-Day average volume of 893,436 shares. On average, long-term indicators rated the stock as “33% Buy ”. The overall picture from all short, medium and long-term indicators sets the ZSAN stock as “48% Buy ” on average basis.
Recently, multiple brokerages have sent out reports on ZSAN. Piper Jaffray, for example, Initiated its rating on shares of Zosano Pharma Corporation to a “Overweight”, while setting a $4 price target on shares of the company’s stock, according to a research note from Friday March 24th, 2017. while giving the stock a “ Neutral” from “Buy ” rating, as stated in a research report from Thursday, August 11th, 2016. ROTH Capital, on the other hand, Reiterated a “Buy” rating on this stock, while posting a $7 price target on shares of this company’s stock in a research note dated Wednesday, November 11th, 2015.
In other news related to Zosano Pharma Corporation stock, 67.28% shares of ZSAN held by institutions. The total number of institutions who held the ZSAN shares was 31, according to most recent SEC filling. During the past quarter, total 8,055,459 shares held by institutions with the net change of 911,357 shares. In the meantime, 3 new institutions bought the shares of Zosano Pharma Corporation for the first time and 6 institutions sold all their holdings in the company’s common stock. 6 institutions increased their investment in the ZSAN stock and 13 institutions decreased their investment in the Zosano Pharma Corporation (ZSAN)’s stock during the last quarter.